Skip to main content

Incyte s Revenues Take a Dive, Losses Narrow in Q1

NEW YORK, May 4 (GenomeWeb News) - Incyte's revenues were almost cut in half, while its losses narrowed during Q1 of 2004, the company reported today.


Revenues for the quarter plummeted to $6.6 million, from $12.5 million during the same period last year. Incyte attributed this decrease to the discontinuation of its genomic data products.


R&D costs decreased to $26.2 million, down from $30.2 million during the first quarter of 2003.


Incyte's net loss decreased to $37.7 million, or $.52 per share, from $55.8 million, or $.81 per share, during the year-ago period.


As of March 31, Incyte had $500.7 million in cash, cash equivalents and marketable securities, compared to $293.8 million at the end of 2003. This increase results from the company's sale of convertible subordinated notes, which generated net proceeds of $242 million.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.